Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4][10]. Core Insights - The company reported a revenue of 5.539 billion yuan for 2024, representing a year-on-year growth of 57.2%. The net profit attributable to shareholders for the same period is projected at 2.062 billion yuan, a 42% increase [2][4]. - The company has adjusted its profit forecasts for 2025 and 2026 upwards, with expected net profits of 2.567 billion yuan and 3.142 billion yuan respectively, reflecting growth rates of 24% and 22% [4][7]. - The report highlights a strong performance in direct-to-consumer (DTC) channels, with revenue from DTC stores and e-commerce platforms growing by 66% and 112% respectively [8]. Financial Performance - For 2024, the company expects a gross margin of 82.1%, slightly down from the previous year, with a sales expense ratio increasing to 36.26% due to higher online marketing investments [8]. - The company has entered approximately 1,700 public hospitals and 3,000 private hospitals, indicating a robust expansion strategy [8]. - The revenue from key products, such as 可复美 and 可丽金, reached 4.542 billion yuan and 841 million yuan respectively, with growth rates of 63% and 36% [8]. Profitability Metrics - The diluted earnings per share for 2024 is projected at 1.99 yuan, with a return on equity (ROE) of 29.01% [7][8]. - The company’s price-to-earnings (P/E) ratio is expected to be 25.06 for 2024, decreasing to 17.36 by 2027, indicating a favorable valuation trend [7][8]. Market Position and Strategy - The company is focusing on enhancing brand strength through scientific skincare communication and product innovation, with a strong emphasis on proprietary research and development [8]. - The report notes that the company is well-positioned in the medical dressing market, with leading market share and a healthy customer structure [8].
巨子生物（02367）：24年业绩延续亮眼，品牌势能持续释放